Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
AVROBIO Inc
NASDAQ AVRO
Data sourced from
and
and
Download Data
AVROBIO Inc Price to Earnings Ratio (P/E) on June 03, 2024: 0.98
AVROBIO Inc Price to Earnings Ratio (P/E) is 0.98 on June 03, 2024, a 117.99% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
-
AVROBIO Inc 52-week high Price to Earnings Ratio (P/E) is 1.38 on April 04, 2024, which is 41.32% above the current Price to Earnings Ratio (P/E).
-
AVROBIO Inc 52-week low Price to Earnings Ratio (P/E) is -6.32 on June 09, 2023, which is -745.95% below the current Price to Earnings Ratio (P/E).
-
AVROBIO Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is 0.32.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: AVRO
| CEO | Mr. Geoff MacKay BSc |
| IPO Date | June 21, 2018 |
| Location | United States |
| Headquarters | Building 300, Cambridge, MA, United States, 02139 |
| Employees | 13 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key trends
Similar companies
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email